{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010330","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.141273+00:00","generated_at":"2026-06-17T13:38:51.268274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProKidney reports Q4 net loss of $24.6M; cash $490.3M; Phase 3 trials advancing","bullets":["Cash and cash equivalents $490.3M as of Dec 31, 2022, vs $20.6M year-end 2021.","R&D expense $20.9M in Q4 2022, up from $10.7M in Q4 2021 due to clinical trial costs and hiring.","Net loss before noncontrolling interest $24.6M for Q4 2022, compared to $13.7M for Q4 2021.","Proact1 Phase 3 trial enrolling; interim data expected end of 2024; proact2 trial progressing toward initiation.","REACT received RMAT designation; EMA provided favorable scientific advice for Phase 3 program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010330","json":"https://secwatch.observer/filing/0000950170-23-010330.json","markdown":"https://secwatch.observer/filing/0000950170-23-010330.md","text":"https://secwatch.observer/filing/0000950170-23-010330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/prok-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:38:51.268274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08fe7072852a63ab53897ae0fecfb9cc5c61dc61","claim":"PROKIDNEY CORP. reported the fourth quarter ended December 31, 2022 results: net income $24.6 million.","evidence_excerpt":"Net loss before noncontrolling interest was $24.6 million and $13.7 million for the three months ended December 31, 2022, and 2021, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$24.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"59cce32f5dbbd9af093866d119f416134cf801dc","claim":"PROKIDNEY CORP. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"On March 28, 2023, ProKidney Corp. issued a press release to announce its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}